Harbour BioMed and ProBioGen Agree on a GlymaxX® License to Fast-Track Cell Line Development Projects

BERLIN, Germany and SHANGHAI, China, February 02, 2021 / B3C newswire / -- ProBioGen AG and Harbour BioMed today jointly announced their agreement on a cell line development project and application of the ADCC-enhancement technology GlymaxX®.

Harbour BioMed contracted ProBioGen for the advancement of one of their clinical programs, an antibody with ADCC as mode-of-action. For the enhancement of such antibody’s ADCC, ProBioGen will apply its proprietary GlymaxX® technology. The GlymaxX® technology enables flexible and reversible adjustment of the antibody fucosylation level – from afucosylated to fully fucosylated. This technology is compatible with the CHO.RiGHT® cell line development platform and DirectedLuck™ Transposase. With DirectedLuck™, ProBioGen is now offering fast-track programs, also realized for this Harbour BioMed project.

Jingsong Wang, Founder, CEO and Chairman at Harbour BioMed said: “The combination of ProBioGen’s reputation for outstanding cell lines and their technologies offered alongside our own platforms, convinced us of the rapid progress we can make to bring this and other antibody candidates to the clinic. We are looking forward to working with the ProBioGen team through this exciting collaboration.”

“The ProBioGen team is thrilled to start this cooperation with Harbour BioMed. Using our elegant technologies that combine high, tunable potency and superior productivity with highest development speed, we are happy to advance Harbour BioMed’s pipeline, developed with their clever Harbour Mice® platform”, continued Dr. Volker Sandig, Chief Scientific Officer of ProBioGen and co-inventor of GlymaxX® and DirectedLuck™.

About ProBioGen AG
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP manufacturing of biopharmaceuticals. Our proprietary technologies like CHO.RiGHT®, the genetic glyco-engineering GlymaxX® and the targeted transposase DirectedLuck™ in combination with our efficient process development and robust GMP manufacturing accelerate and advance the development of drug candidates – from early concept to industrial market-readiness.

ProBioGen provides modern manufacturing solutions for viral vectors with its continuous AGE1.CR® duck cell line, a vaccine platform with MVA-CR19 and renders technology support in gene therapy and vaccine development.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen is successfully serving international clients for more than 26 years, is privately owned and based in Berlin.

About Harbour BioMed
Harbour BioMed is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company is building its pipeline through internal R&D programs and collaborations with co-discovery and co-development partners.

The company’s internal discovery programs are centered around its two patented transgenic mouse platforms (Harbour Mice®) for generating both fully human monoclonal antibodies and heavy chain only antibodies (HCAb) and HBICE™ immune cell engager technology for developing bispecific antibodies. Harbour BioMed also licenses the platforms to companies and academic institutions.  The company has operations in Cambridge, Massachusetts, USA; Rotterdam, The Netherlands; and Suzhou & Shanghai, China.

Contacts

ProBioGen AG
Dr. Gabriele Schneider
Chief Business Officer
Herbert-Bayer-Str. 8
13086 Berlin, Germany
+49 (0)30 3229 35 100
glymaxx@probiogen.de
www.probiogen.de

Harbour BioMed
Atul Deshpande PhD, MBA
Chief Strategy Officer and Head, US Ops.
+1 908 210 3347
atul.deshpande@harbourbiomed.com
www.harbourbiomed.com

Keywords: Cell Line; Cell Proliferation; Recombinant Proteins; Transgenes; Biological Products; Cells, Cultured; cell line development; Productivity; Antibody-Dependent Cell Cytotoxicity; Fucose; Commerce; Germany

Published by B3C newswire